Plitidepsin
- Generic Name
- Plitidepsin
- Drug Type
- Small Molecule
- Chemical Formula
- C57H87N7O15
- CAS Number
- 137219-37-5
- Unique Ingredient Identifier
- Y76ID234HW
- Background
Aplidine is a peptide found in tunicates which shows promise in shrinking tumors in pancreatic, stomach, bladder, and prostate cancers. The specific marine organism is Aplidium albicans. Aplidine is also of interest as a potential treatment for some leukemias.
- Indication
Intended for the treatment of various forms of cancer.
Study to Evaluate the Efficacy and Safety of Plitidepsin in Adults with Post-COVID-19 Condition (PCC)
- Conditions
- Post COVID-19 ConditionLong COVID SyndromePersistent COVID-19Persistent COVID ConditionLong COVID
- Interventions
- First Posted Date
- 2025-01-09
- Last Posted Date
- 2025-02-27
- Lead Sponsor
- Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia
- Target Recruit Count
- 90
- Registration Number
- NCT06766825
- Locations
- 🇪🇸
Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain
Plitidepsin Versus Control in Immunocompromised Adult Participants With Symptomatic COVID-19 Requiring Hospital Care (NEREIDA)
- First Posted Date
- 2023-01-30
- Last Posted Date
- 2024-12-02
- Lead Sponsor
- PharmaMar
- Target Recruit Count
- 37
- Registration Number
- NCT05705167
- Locations
- 🇮🇹
IRCCS Istituto Nazionale per le Malattie Infettive Lazzaro Spallanzani, Roma, Rome, Italy
🇧🇪Universitair Ziekenhuis Leuven - Campus Gasthuisberg, Leuven, Flemish Brabant, Belgium
🇫🇷Centre Hospitalier de la Côte Basque, Bayonne, Pyrénées-Atlantiques, France
Extension Study in a Cohort of Adult Patients With COVID-19 Infection
- Conditions
- COVID-19 Infection
- Interventions
- First Posted Date
- 2021-11-16
- Last Posted Date
- 2024-12-31
- Lead Sponsor
- PharmaMar
- Target Recruit Count
- 34
- Registration Number
- NCT05121740
- Locations
- 🇪🇸
Hospital Universitario Quironsalud Madrid, Pozuelo De Alarcón, Madrid, Spain
🇪🇸Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain
🇪🇸Hospital Universitario HM Montepríncipe, Boadilla del monte, Madrid, Spain
Trial to Determine the Efficacy/Safety of Plitidepsin vs Control in Patients With Moderate COVID-19 Infection
- Conditions
- COVID-19 Infection
- Interventions
- First Posted Date
- 2021-03-05
- Last Posted Date
- 2025-02-21
- Lead Sponsor
- PharmaMar
- Target Recruit Count
- 205
- Registration Number
- NCT04784559
- Locations
- 🇧🇷
Hospital Felicio Rocho, Belo Horizonte, MG, Brazil
🇲🇽Universidad Autonoma de Nuevo Leon - Hospital Universitario "Dr. Jose Eleuterio Gonzalez", Monterrey, NL, Mexico
🇷🇴Institutul National De Boli Infectioase "Prof. Dr. Matei Bals", Bucharest, Romania
Proof of Concept Study to Evaluate the Safety Profile of Plitidepsin in Patients With COVID-19
- Conditions
- COVID-19
- Interventions
- First Posted Date
- 2020-05-11
- Last Posted Date
- 2022-08-23
- Lead Sponsor
- PharmaMar
- Target Recruit Count
- 46
- Registration Number
- NCT04382066
- Locations
- 🇪🇸
Hospital Gregorio Marañón, Madrid, Spain
🇪🇸Hospital Clínic de Barcelona, Barcelona, Spain
🇪🇸Hospital Universitario Hm Montepríncipe, Boadilla Del Monte, Madrid, Spain
Trial of Plitidepsin (Aplidin®) in Combination With Bortezomib and Dexamethasone in Multiple Myeloma Patients Double Refractory to Bortezomib and Lenalidomide
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2017-04-17
- Last Posted Date
- 2020-12-02
- Lead Sponsor
- PharmaMar
- Target Recruit Count
- 10
- Registration Number
- NCT03117361
- Locations
- 🇫🇷
CHRU de Lille - Hôpital Claude Huriez, Lille, France
🇫🇷Institut Gustave Roussy, Villejuif, France
🇮🇹Policlinico Vittorio Emanuele Hospital, Catania, Italy
A Study of Plitidepsin in Patients With Relapsed or Refractory Angioimmunoblastic T-cell Lymphoma
- First Posted Date
- 2017-03-06
- Last Posted Date
- 2020-10-14
- Lead Sponsor
- PharmaMar
- Target Recruit Count
- 14
- Registration Number
- NCT03070964
- Locations
- 🇺🇸
Northwestern University Medical School, Chicago, Illinois, United States
🇺🇸Fred Hutchinson Cancer Research Center, Seattle, Washington, United States
🇨🇿Faculty Hospital Ostrava, Ostrava, Czechia
Study of Plitidepsin (Aplidin®) in Combination With Bortezomib and Dexamethasone in Patients With Multiple Myeloma
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2014-04-01
- Last Posted Date
- 2020-10-12
- Lead Sponsor
- PharmaMar
- Target Recruit Count
- 39
- Registration Number
- NCT02100657
- Locations
- 🇫🇷
Institut Gustave Roussy, Villejuif, France
🇪🇸Hospital Universitario Germans Trias I Pujol, Badalona, Barcelona, Spain
🇪🇸Clínica Universidad de Navarra, Pamplona, Navarra, Spain
Efficacy and Safety of Plitidepsin in Patients With Advanced Unresectable or Metastatic, Relapsed/Refractory, Dedifferentiated Liposarcoma (DLPS): an Exploratory Phase II Multicenter Trial
- Conditions
- Adult Patients With Unresectable Locally Advanced or Metastatic, Relapsed/Refractory Dedifferentiated Liposarcoma
- Interventions
- First Posted Date
- 2013-06-12
- Last Posted Date
- 2021-01-25
- Lead Sponsor
- Institut Bergonié
- Target Recruit Count
- 24
- Registration Number
- NCT01876043
- Locations
- 🇫🇷
Institut Claudius Regaud, Toulouse, France
🇫🇷Hôpital de la Timone, Marseille, France
🇫🇷Centre Oscar Lambret, Lille, France
Aplidin - Dexamethasone in Relapsed/Refractory Myeloma
- Conditions
- Relapsed/Refractory Multiple Myeloma
- Interventions
- First Posted Date
- 2010-04-13
- Last Posted Date
- 2020-11-10
- Lead Sponsor
- PharmaMar
- Target Recruit Count
- 255
- Registration Number
- NCT01102426
- Locations
- 🇬🇧
1003, Bournemouth, United Kingdom
🇦🇹201, Wien, Austria
🇺🇸1102, New York, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.